Respiratory Archives - Page 5 of 9

Efficacy and safety of rituximab in the treatment of connective tissue disease-related interstitial lung disease

Caterina Vacchi PhD, Andreina Manfredi MD, Giulia Cassone PhD, Gian Luca Erre MD, Carlo Salvarani MD, Marco Sebastiani MD

Article Type

Review

Published

15 Jan 2021

This article reviews the available efficacy and safety data on the use of rituximab in the treatment of rheumatic disease-related interstitial lung disease.

Antifibrotic drugs in connective tissue disease-related interstitial lung disease (CTD-ILD): from mechanistic insights to therapeutic applications

Gian Luca Erre MD, PhD, Marco Sebastiani PhD, Andreina Manfredi MD, Elisabetta Gerratana MD, Fabiola Atzeni MD, Giuseppe Passiu MD, Arduino A Mangoni MD

Article Type

Review

Published

15 Jan 2021

This review discusses the experimental evidence and clinical trials investigating the efficacy and safety of antifibrotic drugs in patients with CTD-ILDs and the potential mechanisms of action involved.

Dabigatran, the oral anticoagulant of choice at discharge in patients with non-valvular atrial fibrillation and COVID-19 infection: the ANIBAL* protocol

Teodoro Iturbe-Hernandez MD, Luis García de Guadiana Romualdo MD, Ignacio Gil Ortega MD, Antonio Martínez Francés MD, Olga Meca Birlanga MD, Juan José Cerezo-Manchado MD

Article Type

Original Research

Published

18 Sep 2020

In this review, the available information on the antithrombotic management of atrial fibrillation patients at discharge after COVID-19 infection is updated. In addition, a practical algorithm, considering renal and liver function, which facilitates the anticoagulation choice at discharge is presented.

Mepolizumab: an alternative therapy for idiopathic chronic eosinophilic pneumonia with glucocorticoid intolerance

Adam Kisling MD, Jason Jones MD, Caleb Hixson DO FCAP, David Hostler MD MPH FACP, Jordanna Hostler MD FACP

Article Type

Case Report

Published

18 Aug 2020

This article presents a case of ICEP in which mepolizumab was used as a steroid-sparing agent, resulting in improvement in markers of disease activity
and corticosteroid requirement.

Can vitamins and/or supplements provide hope against coronavirus?

Sarah M Michienzi PharmD, Melissa E Badowski PharmD

Article Type

Review

Published

22 Jun 2020

The goal of this narrative review is to evaluate current and ongoing clinical trials of vitamins and supplements, alone or in combination with each other or other therapies, for the treatment of COVID-19.